News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
272,166 Results
Type
Article (14448)
Company Profile (282)
Press Release (257435)
Multimedia
Podcasts (56)
Webinars (9)
Section
Business (79693)
Career Advice (157)
Deals (13271)
Drug Delivery (35)
Drug Development (50548)
Employer Resources (31)
FDA (5758)
Job Trends (5153)
News (144721)
Policy (10054)
Tag
Academia (925)
Accelerated approval (3)
Adcomms (14)
Allergies (60)
Alliances (21767)
ALS (80)
Alzheimer's disease (888)
Antibody-drug conjugate (ADC) (126)
Approvals (5795)
Artificial intelligence (152)
Autoimmune disease (26)
Automation (5)
Bankruptcy (105)
Best Places to Work (4566)
BIOSECURE Act (6)
Biosimilars (54)
Biotechnology (232)
Bladder cancer (67)
Brain cancer (27)
Breast cancer (204)
Cancer (1872)
Cardiovascular disease (139)
Career advice (137)
Career pathing (2)
CAR-T (145)
CDC (4)
Cell therapy (387)
Cervical cancer (9)
Clinical research (41726)
Collaboration (681)
Company closure (1)
Compensation (338)
Complete response letters (15)
COVID-19 (1052)
CRISPR (60)
C-suite (218)
Cystic fibrosis (87)
Data (2070)
Denatured (12)
Depression (44)
Diabetes (177)
Diagnostics (1315)
Digital health (3)
Diversity (3)
Diversity, equity & inclusion (9)
Drug discovery (98)
Drug pricing (32)
Drug shortages (3)
Duchenne muscular dystrophy (116)
Earnings (30387)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (49536)
Executive appointments (542)
FDA (6684)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (612)
Gene editing (122)
Generative AI (10)
Gene therapy (315)
GLP-1 (409)
Government (1101)
Grass and pollen (2)
Guidances (76)
Healthcare (6643)
Huntington's disease (29)
IgA nephropathy (38)
Immunology and inflammation (113)
Immuno-oncology (5)
Indications (24)
Infectious disease (1124)
Inflammatory bowel disease (123)
Inflation Reduction Act (9)
Influenza (24)
Intellectual property (82)
Interviews (19)
IPO (7321)
IRA (11)
Job creations (865)
Job search strategy (130)
Kidney cancer (8)
Labor market (10)
Layoffs (221)
Leadership (3)
Legal (1395)
Liver cancer (34)
Lung cancer (260)
Lymphoma (139)
Machine learning (6)
Management (7)
Manufacturing (184)
MASH (78)
Medical device (2620)
Medtech (2621)
Mergers & acquisitions (6366)
Metabolic disorders (481)
Multiple sclerosis (64)
NASH (13)
Neurodegenerative disease (87)
Neuropsychiatric disorders (29)
Neuroscience (1403)
NextGen: Class of 2025 (2034)
Non-profit (860)
Now hiring (24)
Obesity (224)
Opinion (104)
Ovarian cancer (83)
Pain (52)
Pancreatic cancer (81)
Parkinson's disease (150)
Partnered (8)
Patents (168)
Patient recruitment (111)
Peanut (38)
People (25928)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14756)
Phase II (19412)
Phase III (12246)
Pipeline (1085)
Policy (63)
Postmarket research (853)
Preclinical (6267)
Press Release (30)
Prostate cancer (84)
Psychedelics (39)
Radiopharmaceuticals (220)
Rare diseases (357)
Real estate (1426)
Recruiting (12)
Regulatory (8852)
Reports (18)
Research institute (945)
Resumes & cover letters (17)
Rett syndrome (8)
RNA editing (10)
RSV (10)
Schizophrenia (75)
Series A (119)
Series B (78)
Service/supplier (1)
Sickle cell disease (49)
Special edition (13)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1984)
State (1)
Stomach cancer (5)
Supply chain (24)
Tariffs (14)
The Weekly (43)
Vaccines (243)
Venture capital (40)
Weight loss (114)
Women's health (16)
Worklife (2)
Date
Today (5)
Last 7 days (225)
Last 30 days (1086)
Last 365 days (18593)
2025 (9986)
2024 (20570)
2023 (22435)
2022 (26858)
2021 (27836)
2020 (23390)
2019 (16262)
2018 (11759)
2017 (13761)
2016 (11852)
2015 (14366)
2014 (10407)
2013 (7488)
2012 (7540)
2011 (7623)
2010 (7448)
Location
Africa (148)
Alabama (50)
Alaska (2)
Arizona (56)
Arkansas (5)
Asia (17594)
Australia (2981)
California (4719)
Canada (1335)
China (476)
Colorado (179)
Connecticut (175)
Delaware (137)
Europe (37776)
Florida (593)
Georgia (146)
Hawaii (1)
Idaho (16)
Illinois (282)
India (11)
Indiana (113)
Iowa (6)
Japan (119)
Kansas (65)
Kentucky (6)
Louisiana (4)
Maine (24)
Maryland (546)
Massachusetts (3782)
Michigan (86)
Minnesota (173)
Mississippi (2)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (20)
New Hampshire (14)
New Jersey (1161)
New Mexico (12)
New York (1262)
North Carolina (620)
North Dakota (6)
Northern California (2108)
Ohio (131)
Oklahoma (9)
Oregon (21)
Pennsylvania (882)
Puerto Rico (7)
Rhode Island (21)
South America (209)
South Carolina (6)
Southern California (1797)
Tennessee (29)
Texas (572)
United States (16077)
Utah (68)
Virginia (100)
Washington D.C. (36)
Washington State (408)
West Virginia (1)
Wisconsin (25)
272,166 Results for "maze therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Maze Therapeutics to Participate in Two Upcoming July 2025 Investor Conferences
July 11, 2025
·
1 min read
Press Releases
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
May 29, 2025
·
1 min read
IPO
Maze Opens 2025 IPO Class to Advance Kidney Disease Programs
Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in funding to support the development of its kidney disease pipeline.
January 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
May 14, 2025
·
7 min read
Press Releases
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
May 14, 2025
·
1 min read
Press Releases
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
April 1, 2025
·
10 min read
Press Releases
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
January 30, 2025
·
2 min read
Biotech Bay
Maze Therapeutics to Participate in Upcoming Investor Conferences
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that company management will participate in upcoming investor conferences in February and March 2024.
February 26, 2024
·
1 min read
Press Releases
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
February 7, 2025
·
5 min read
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
1 of 27,217
Next
